Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

Alexander B H Bakker, Marco W J Schreurs, Annemiek J. De Boer, Yutaka Kawakami, Steven A. Rosenberg, Gosse J. Adema, Carl G. Figdor

Research output: Contribution to journalArticle

501 Citations (Scopus)

Abstract

We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.

Original languageEnglish
Pages (from-to)1005-1009
Number of pages5
JournalJournal of Experimental Medicine
Volume179
Issue number3
Publication statusPublished - 1994 Mar 1
Externally publishedYes

Fingerprint

gp100 Melanoma Antigen
Tumor-Infiltrating Lymphocytes
Melanoma
Melanocytes
Cytotoxic T-Lymphocytes
Antigens
Complementary DNA
Immunotherapy
Transfection
Glycoproteins
Clone Cells
Cell Line
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Bakker, A. B. H., Schreurs, M. W. J., De Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994). Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. Journal of Experimental Medicine, 179(3), 1005-1009.

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. / Bakker, Alexander B H; Schreurs, Marco W J; De Boer, Annemiek J.; Kawakami, Yutaka; Rosenberg, Steven A.; Adema, Gosse J.; Figdor, Carl G.

In: Journal of Experimental Medicine, Vol. 179, No. 3, 01.03.1994, p. 1005-1009.

Research output: Contribution to journalArticle

Bakker, ABH, Schreurs, MWJ, De Boer, AJ, Kawakami, Y, Rosenberg, SA, Adema, GJ & Figdor, CG 1994, 'Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes', Journal of Experimental Medicine, vol. 179, no. 3, pp. 1005-1009.
Bakker ABH, Schreurs MWJ, De Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. Journal of Experimental Medicine. 1994 Mar 1;179(3):1005-1009.
Bakker, Alexander B H ; Schreurs, Marco W J ; De Boer, Annemiek J. ; Kawakami, Yutaka ; Rosenberg, Steven A. ; Adema, Gosse J. ; Figdor, Carl G. / Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. In: Journal of Experimental Medicine. 1994 ; Vol. 179, No. 3. pp. 1005-1009.
@article{007448e4f1ac45e8b42b3ed02af94c11,
title = "Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes",
abstract = "We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.",
author = "Bakker, {Alexander B H} and Schreurs, {Marco W J} and {De Boer}, {Annemiek J.} and Yutaka Kawakami and Rosenberg, {Steven A.} and Adema, {Gosse J.} and Figdor, {Carl G.}",
year = "1994",
month = "3",
day = "1",
language = "English",
volume = "179",
pages = "1005--1009",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

AU - Bakker, Alexander B H

AU - Schreurs, Marco W J

AU - De Boer, Annemiek J.

AU - Kawakami, Yutaka

AU - Rosenberg, Steven A.

AU - Adema, Gosse J.

AU - Figdor, Carl G.

PY - 1994/3/1

Y1 - 1994/3/1

N2 - We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.

AB - We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.

UR - http://www.scopus.com/inward/record.url?scp=0027958312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958312&partnerID=8YFLogxK

M3 - Article

VL - 179

SP - 1005

EP - 1009

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -